{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Conventional+cohort", "query": { "intervention": "Conventional cohort" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 133, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Conventional+cohort&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T10:56:08.661Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03592264", "title": "A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "OBI-3424", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OBI Pharma, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2018-07-02", "completion_date": "2024-03-21", "has_results": false, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-09-08T10:56:08.661Z", "location_count": 5, "location_summary": "La Jolla, California • Los Angeles, California • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03592264" }, { "nct_id": "NCT01132586", "title": "Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1", "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL", "Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA", "Alkylating Agent-Related Acute Myeloid Leukemia", "de Novo Myelodysplastic Syndrome", "Previously Treated Myelodysplastic Syndrome", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 61, "start_date": "2010-05", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-09-08T10:56:08.661Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01132586" }, { "nct_id": "NCT03107988", "title": "NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Filgrastim/pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New Approaches to Neuroblastoma Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Year to 99 Years" }, "enrollment_count": 65, "start_date": "2017-09-05", "completion_date": "2025-01-31", "has_results": true, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-09-08T10:56:08.661Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03107988" }, { "nct_id": "NCT05253495", "title": "Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-hodgkin Lymphoma", "Hodgkin Lymphoma" ], "interventions": [ { "name": "DOC Group B", "type": "DRUG" }, { "name": "Pv-COMRAD 1 and 2 Group B", "type": "DRUG" }, { "name": "Pv-R-CYM 1 and 2 Group B", "type": "DRUG" }, { "name": "DOC Group C", "type": "DRUG" }, { "name": "MAD CPR 1 and 2", "type": "DRUG" }, { "name": "Pv-R CYVE 1 and 2", "type": "DRUG" }, { "name": "Pv-R CYVE-MTX 1 and 2", "type": "DRUG" }, { "name": "MAD CP", "type": "DRUG" }, { "name": "Pv-Cytarabine/etoposide", "type": "DRUG" }, { "name": "AD CP", "type": "DRUG" }, { "name": "Bv-AVD-R 1 and 2: COHORT IIa", "type": "DRUG" }, { "name": "Bv-NVD-R, Cycle 1-2", "type": "DRUG" }, { "name": "Bv-NVD-R, Cycle 1-4 SER", "type": "DRUG" }, { "name": "Bv-AVD-R", "type": "DRUG" }, { "name": "Bv-NVD-R, Cycle 1-4 RER", "type": "DRUG" }, { "name": "Bv-NAVD-R, Cycle 1-2", "type": "DRUG" }, { "name": "Involved Site Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 80, "start_date": "2022-02-01", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2025-06-13", "last_synced_at": "2026-09-08T10:56:08.661Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Gainsville, Florida • Vallhala, New York", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gainsville", "state": "Florida" }, { "city": "Vallhala", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05253495" }, { "nct_id": "NCT05404945", "title": "Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 24, "start_date": "2022-07-26", "completion_date": "2027-10-03", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-08T10:56:08.661Z", "location_count": 3, "location_summary": "New Brunswick, New Jersey • Philadelphia, Pennsylvania • Charlottesville, Virginia", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05404945" }, { "nct_id": "NCT02082353", "title": "Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Granulomatous Disease, Chronic" ], "interventions": [], "intervention_types": [], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1480, "start_date": "2014-06", "completion_date": "2021-11", "has_results": false, "last_update_posted_date": "2021-09-02", "last_synced_at": "2026-09-08T10:56:08.661Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082353" }, { "nct_id": "NCT03784326", "title": "Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2019-02-19", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-08T10:56:08.661Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03784326" }, { "nct_id": "NCT04457362", "title": "Wrist Arthroscopy Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Wrist Arthropathy" ], "interventions": [ { "name": "Diagnostic Arthroscopy using the Arthrex NanoScope", "type": "DIAGNOSTIC_TEST" }, { "name": "Diagnostic Arthroscopy using standard arthroscopic instruments", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-10-10", "completion_date": "2023-03-22", "has_results": true, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-09-08T10:56:08.661Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04457362" }, { "nct_id": "NCT02701153", "title": "Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Adult Soft Tissue Sarcoma" ], "interventions": [ { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2016-02-03", "completion_date": "2028-02-03", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-09-08T10:56:08.661Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02701153" }, { "nct_id": "NCT00055237", "title": "Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kaposi's Sarcoma", "HIV Infections", "HIV Seronegativity" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2003-02-26", "completion_date": "2010-03-15", "has_results": true, "last_update_posted_date": "2017-09-06", "last_synced_at": "2026-09-08T10:56:08.661Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055237" } ] }